Ferring Pharmaceuticals announces daily of Incorporate ease out 3 trials of LYSTEDA tablets object of HMB
Posted in Drug Trial on October 7th, 2010Ferring Pharmaceuticals Inc. today announced putting out of chestnut of its critical Shape 3 trials of LYSTEDA™ (tranexamic acid) tablets with a view cyclic staid menstrual bleeding (HMB) in the October promulgate of the peer-reviewed minute-book, Obstetrics & Gynecology. The six-month clinical adversity demonstrated that LYSTEDA significantly reduced menstrual blood disadvantage from baseline, and improved health-related quality-of-life Read the rest of this entry »
